Glucagon-like peptide-1 receptor agonists may have a role in treating peripheral neuropathy in patients with type 2 diabetes, an Australian study suggests.
Findings show mainly structural and morphological improvements in nerve size in the months after starting glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, supported by electrophysiological and clinical measures.
Sydney researchers followed 22 consecutive patients (mean age 60, 64% male) prescribed semaglutide or dulaglutide and assessed with tibial nerve ultrasonography, neuropathy symptom scores and nerve conduction studies.
GLP-1 RA therapy was associated with reversed nerve morphological abnormalities measured via nerve ultrasound, with one month post-treatment assessment demonstrating an improvement of nerve size in 86% of patients.
Almost one-third of participants returned to normal nerve morphology.
Additionally, a three month follow-up study of 14 participants demonstrated further improvement in nerve size in 93% of participants, accompanied by reduced severity of neuropathy and improved sural sensory nerve conduction amplitude.
Patients had a mean tibial nerve cross-sectional area of 15.7 mm2 pretreatment, with an increased nerve size of >12.4 mm2 noted in 81.8% of the cohort, noted the neurologists and endocrinologists from Prince of Wales Hospital and UNSW.
Writing in a short communication for Diabetologia [link here], the team said mean tibial nerve cross-sectional area reduced from 15.7 mm2 to 12.6 mm2 one month following treatment. In 31.8% of patients, the magnitude of improvement was sufficient to restore the nerve cross-sectional area to normal values <12.4 mm2.